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Abstract
Background: We have previously demonstrated that four members of the family of small leucine-rich-
proteoglycans (SLRPs) of the extracellular matrix (ECM), named decorin, biglycan, lumican and fibromodulin, are
deeply remodeled in mouse uterine tissues along the estrous cycle and early pregnancy. It is known that the
combined action of estrogen (E2) and progesterone (P4) orchestrates the estrous cycle and prepares the
endometrium for pregnancy, modulating synthesis, deposition and degradation of various molecules. Indeed, we
showed that versican, another proteoglycan of the ECM, is under hormonal control in the uterine tissues.
Methods: E2 and/or medroxiprogesterone acetate (MPA) were used to demonstrate, by real time PCR and
immunoperoxidase staining, respectively, their effects on mRNA expression and protein deposition of these SLRPs,
in the uterine tissues.
Results: Decorin and lumican were constitutively expressed and deposited in the ECM in the absence of the
ovarian hormones, whereas deposition of biglycan and fibromodulin were abolished from the uterine ECM in the
non-treated group. Interestingly, ovariectomy promoted an increase in decorin, lumican and fibromodulin mRNA
levels, while biglycan mRNA conspicuously decreased. Hormone replacement with E2 and/or MPA differentially
modulates their expression and deposition.
Conclusions: The patterns of expression of these SLRPs in the uterine tissues were found to be hormone-
dependent and uterine compartment-related. These results reinforce the existence of subpopulations of
endometrial fibroblasts, localized into distinct functional uterine compartments, resembling the organization into
basal and functional layers of the human endometrium.
Background
The reproductive cycle of human and rodents is charac-
terized by recurring morphophysiological changes in the
reproductive organs. The combined action of estrogen
(E2) and progesterone (P4) orchestrates the cycle and
prepares the endometrium for pregnancy. In the mouse,
the cycle is known as estrous cycle and is divided into
four different phases, denominated proestrus, estrus,
metaestrus and diestrus, each one presenting distinct
morphological and molecular features [1].
E2 produced during estrus stimulates epithelial cell pro-
liferation and synthesis of progesterone receptors (PR). On
the other hand, P4 inhibits epithelial proliferation and
stimulates the multiplication of endometrial stromal cells
[2,3]. Estrogen receptors (ER) and PR are transcription fac-
tors that regulate gene expression by direct binding to
DNA regulatory sequences or by specific interactions with
co-activators and/or co-repressor proteins [4,5]. It has been
previously demonstrated that the uterus of ERa knock-out
mice is hypoplastic, the endometrial stroma is disorganized,
and the luminal epithelium is formed by cuboidal cells,
which are unable to acquire a tall columnar phenotype [6].
PR knock-out mice showed that P4 is a crucial regulator of
reproductive functions, as these animals are unable to ovu-
late, present uterine dysfunction, and altered endothelial
and smooth muscle cell proliferation [7]. Moreover, our
group showed a clear compartmentalization in the expres-
sion of estrogen receptors in the mouse uterine tissues [8].
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oid hormone in the uterine tissues, we emphasize the
remodeling of extracellular matrix (ECM) molecules.
The ECM is a complex structure of secreted macromo-
lecules, immobilized in the extracellular space, and com-
posed predominantly of collagens, non-collagenous
multiadhesive glycoproteins, elastin, hyaluronan and
proteoglycans [9].
Decorin, biglycan, lumican and fibromodulin are
members of the family of small leucine-rich-proteogly-
cans (SLRPs) of the ECM [10,11]. The SLRP family
comprises about seventeen genes that share structural
homologies, such as cysteine residues, leucine rich
repeats and at least one glycosaminoglycan side chain.
These proteoglycans are divided into five distinct
classes. Decorin and biglycan belong to class I, present-
ing similarities in their amino acid sequence, in the
chondroitin or dermatan sulfate side chains and a typi-
cal cluster of cysteine residues at the N-terminus that
form two disulfide bonds. Fibromodulin and lumican
belong to class II, both presenting keratan sulfate and
polylactosamine side chains, as well as clusters of tyro-
sine-sulfate residues at their N-termini [12].
Some SLRPs act as a growth factor reservoir in the
ECM, modulating biological processes, such as cell prolif-
eration and differentiation [10,13]. They are capable of
inducing signaling cascades through tyrosine kinase, toll-
like and TGF-b/BMP receptors [12]. There is strong evi-
dence that collagen fibril-associated decorin is able to
arrest TGF-b in the ECM, inhibiting its proliferative activ-
ity [14]. Biglycan, on the other hand, has been related to
the activity of BMPs in the control of embryo development
[15]. In addition, these molecules also participate in the
process of collagen fibrillogenesis [10]. The orientation
and aggregation of collagen fibrils is partly determined by
proteoglycans, as they form interfibrillar bridges [16].
Lumican and fibromodulin, for instance, are known to
compete in vitro for the same attachment sites at the col-
lagen fibril, hindering fibrillar lateral growth [13,17,18].
It is known that the endometrial ECM plays important
roles in decidualization, embryo implantation and tro-
phoblast cell invasion [19]. For that purpose the endo-
metrium must undergo complex cycles of ECM
breakdown and re-arrangement, through coordinated
synthesis, deposition and cleavage of its molecules.
Considering the actions of ovarian hormones in the
remodeling of uterine tissues, it is reasonable to indicate
that proteoglycans are modulated in the uterine ECM by
these steroid hormones, whose levels fluctuate constantly
in the non-pregnant and pregnant endometrium. Con-
firming this hypothesis our group has demonstrated that
versican expression and deposition are under hormonal
control in the mouse uterine tissues [20]. P4 stimulates
versican deposition in the endometrium, whereas the
myometrium responds exclusively to E2, evidencing that
the changes observed in the cellular and ECM organiza-
tion of the uterine tissues require exposure to a defined
hormonal regimen.
We have previously shown the differential distribution
of these SLRPs in the mouse endometrium (stroma and
epithelia) and myometrium during the estrous cycle [21]
and the early stages of pregnancy [22]. In this context,
the aim of this study is to characterize the effects of E2
and/or medroxiprogesterone acetate (MPA) treatment
on the expression and distribution of decorin, biglycan,
lumican and fibromodulin in the uterine tissues of ovar-
iectomized mice.
Methods
Animals and tissue collection
Swiss female mice, aged 3-5 months, were used in this
study. Animals were housed in a 12-h light: 12-h dark,
temperature-controlled (22°C) environment, with free
access to food and water. The stages of the estrous cycle
were determined by vaginal smears. Animals in estrus
and diestrus (physiological control of E2 and P4 levels,
respectively), and ovariectomized animals submitted or
not to hormone treatment were anesthetized with an
intraperitoneal injection of tribromoethanol (Avertin
®)
(Aldrich Chemical Company, Inc., Milwaukee, Wi, USA;
0,025 mL/g body weight). The uteri were subsequently
removed, cut with razor blades and immediately
immersed in a fixative solution or in RNAlater solution
(Sigma-Aldrich, St. Louis, MO, USA). National guide-
lines for laboratory animal care were followed, and all
experiments were approved by the Institute of Biomedi-
cal Sciences Animal Ethics Committee (authorization
number, 144/2002).
Ovariectomy and hormone replacement
The general protocol adopted by us [23] was adapted
from Domino and Hurd [24]. During standardization of
this experimental protocol, the established doses were
10 μgo f1 7 b-estradiol (Sigma-Aldrich) and 0.5 mg of
medroxyprogesterone acetate (MPA) (Pharmacia &
U p j o h n ) ,ap r o g e s t e r o n ea n a l o g .T h ec h o i c ew a sb a s e d
on vaginal smear features and uterine morphology,
which were similar to what was observed in the cycling
mice [21]. Mice were ovariectomized and divided into
five experimental groups, as follows:
1. Tissue collection twenty days after ovariectomy
without hormone treatment.
2. Pre-treatment with daily priming doses of E2,
diluted in mineral oil (Schering-Plough), for three days,
followed by a two-day rest and daily injections of E2
during four consecutive days.
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lowed by a resting period and daily injections of MPA,
diluted in distilled water, during four consecutive days.
4. Same pre-treatment and resting period as the pre-
vious groups, followed by daily injections of both E2
and MPA during four consecutive days.
5. Control group received injections of vehicle alone
(mineral oil) for three days, followed by a two-day rest
and daily oil injections during four consecutive days.
A l li n j e c t i o n sw e r es u b - c u t a n e o u si na1 0 0μl volume.
Twenty four hours after the last injection, the mice were
anesthetized and the uterine samples were collected as
described above.
Light microscopy processing
The samples were fixed at 4°C for 3 h in Methacarn
(absolute methanol, chloroform and glacial acetic acid;
6:3:1), rinsed with absolute ethanol, and embedded in
Paraplast (Oxford, St. Louis, MO, USA) at 60°C. 5 μm
sections were adhered onto glass slides pre-coated with
0.1% poly-L-lysine (Sigma, St. Louis, MO, USA) and
then dried at 37°C.
Immunoperoxidase procedure
The immunoperoxidase staining was performed as pre-
viously described [21]. Sections were treated with 3% (v/v)
H2O2 in PBS (30 min) to block endogenous peroxidase
activity. Each of the succeeding steps was followed by a
thorough rinse in PBS. All steps were performed in a
humidified chamber. Samples were pretreated with Chon-
droitinase ABC from Proteus vulgaris (Seikagaku, Tokyo,
Japan), diluted in 20 mM pH 6,0 Tris-HCl buffer (1 h at
37°C). Nonspecific staining was blocked by incubating the
sections for 1 h with normal rabbit serum (for lumican) or
goat serum (for the other molecules), diluted 1:1 (v/v) in
PBS - 10% BSA (w/v) (room temperature). Sections were
then incubated with primary antibodies (Table 1) diluted
in PBS containing 0.3% (v/v) Tween 20, overnight (4°C).
After extensive rinsing in PBS all sections were incubated
for 1 h at room temperature with the specific biotin-
conjugated secondary antibody (Table 1) diluted in PBS,
for 1 h at room temperature. After rinsing in PBS, sections
were incubated with Vectastain ABC kit (Vector Labora-
tories, Burlingame, CA, USA) for 1 h at room temperature.
The peroxidase reaction was visualized using 0.03% (w/v)
3,3’-diaminobenzidine in PBS with 0.03% (v/v) H2O2.I n
order to achieve standardization of the immunoreactions,
for each antibody, the slides were simultaneously
incubated with DAB, and reaction was immediately
interrupted with PBS after a specific period of time
(1-5 minutes, depending on the antibody). Afterwards,
sections were lightly counterstained with Mayer’s haema-
toxilin (Merck, Darmstadt, Germany). For each immuno-
histochemical reaction, control reactions were performed
by omitting the primary antibody step from the protocol.
In addition, paraffin sections of mouse embryos were used
as positive and negative control.
The immunostained sections were examined in a
Nikon Eclipse E600 microscope and the images were cap-
tured using a digital camera (Cool SNAP-Procf color;
Roper Scientific, Trenton, NJ, USA) and Image Pro Plus
software (Media Cybernetics, Silver Spring, MD, USA).
Antibodies
Table 1 lists the antibodies used in the present study.
Decorin, biglycan and fibromodulin antibodies (LF-113,
LF-159 and LF-150, respectively) were raised in rabbit and
recognize the core protein of each macromolecule. These
antibodies were previously tested by Western blot by the
producers. Detail of the procedures made by Larry Fisher
(National Institute of Dental and Craniofacial Research,
NIH, Bethesda, USA) may be found in Fisher et al [23].
The anti-mouse lumican antibody (R&D Systems,
#AF2745) is an IgG produced in goats, immunized with
purified, NS0-derived, recombinant mouse Lumican
(rmLumican). The mouse lumican specific IgG was puri-
fied by affinity chromatography. The specificity was
tested by direct ELISA and Western blot.
mRNA extraction and real-time PCR
For the molecular biology experiments, the phases of
estrus (highest estrogen levels) and diestrus (highest
progesterone levels) were chosen to represent the
estrous cycle.
Upon use, uterine samples (n = 6 per group), excised with
sterilized razor blades and stored in RNAlater solution at
-20°C, were transferred to sterile microfuge tubes contain-
ing ceramic beads and 500 μl of Trizol reagent (Invitrogen,
Calbard, CA, USA). Samples were homogenized and total
RNA extracted using the Precellys 24 homogenizer (Bertin
Technologies, Saint-Quentin-en-Yvelines, France), following
the manufacturer’s instructions. RNA quantity and quality
were assessed with a NanoDrop spectrophotometer
Table 1 Antibodies
Primary Ab [ ] Second Ab - Biotin Conjugated
(Rockland§)
[]
Anti-decorin
(LF-113∞)
1:3000 Anti-rabbit
(goat)
1:2000
Anti-biglycan
(LF-159∞)
1:1000 Anti-rabbit
(goat)
1:2000
Anti-lumican
(R&D Systems¥)
1:1500 Anti-goat
(rabbit)
1:2000
Anti-fibromodulin
(LF-150∞)
1:400 Anti-rabbit
(goat)
1:2000
∞ Dr. Larry Fisher (National Institute of Dental and Craniofacial Research, NIH,
Bethesda, MD).
¥ R&D Systems - Minneapolis, MN, USA.
§ Rockland - Gilbertsville, PA, USA.
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(RT-PCR) was performed with AffinityScript QPCR cDNA
Synthesis kit (Stratagene, Cedar Creek, TX, USA) and 1 μg
of total RNA. Different reference genes were tested and
Ywhaz (Tyrosine 3-monooxygenase/tryptophan 5-monooxy-
genase activation protein, zeta polypeptide) was chosen as
internal control for showing the most uniform expression
across groups in the PCR amplification experiments. The
relative expression of the SLRPs mRNA was determined as
described previously [25]. The relative levels of mRNA of
the tested genes were estimated in duplicate samples by
fluorescence quantified with the ABI Prism 7500 sequence
detector (Applied Biosystems, Ontario, Canada). Reactions
were performed in a total volume of 25 μl containing 20 ng
of cDNA and 450 nM primers in a reaction buffer contain-
ing SYBR Green PCR master mix (Stratagene). All Cq
(quantification cycle, according to the MIQE guidelines
[26]) values were normalized to the expression of the refer-
ence gene and the results were expressed as fold-induction
relative to the expression of the calibrator sample (estrus),
arbitrarily set to 1. Primers were designed with NCBI’sp r i -
mer designing tool to span an exon-exon junction, in order
to limit amplification only to mRNA. Primer sequences are
given in Table 2.
Statistical analysis
Multiple comparisons were performed by one-way analysis
of variance (ANOVA) followed by the Student Newman
Keuls post-test to determine significant differences among
all groups, using Prism 4.0 (GraphPad Software, San
Diego, CA, USA). All results are expressed as the mean ±
standard error of the mean (SEM). Values of p less than or
equal to 0.05 were considered statistically significant.
Results
Two morphologically distinct compartments can be
identified in the endometrial stroma, herein denoted as
superficial and deep stroma; in the myometrium, three
distinct layers are observed, denominated internal mus-
cle layer, external muscle layer and connective tissue
between layers or vascular plexus [21,20].
Decorin immunolocalization
Ovariectomy did not suppress the deposition of decorin
in the uterine tissues. In the non-treated groups (ovx
and oil), the immunoreaction was present in the deep
stroma and only traces were observed in the superficial
stroma. In the myometrium, the immunoreaction was
present in the external muscle layer (EML) and connec-
tive tissue between layers, but was not observed in the
ECM of the internal muscle layer (IML) (Figure 1A).
In the E2-treated group, strong immunoreaction was
present in the whole endometrial stroma, observed as
a network of thin brownish filaments. The immunor-
eaction was more intense around the luminal and
glandular epithelia, as well as around blood vessels.
The staining was also strong in the myometrium, espe-
cially around bundles of smooth muscle cells in the
EML (Figure 1B).
In the MPA-treated group, the immunoreaction was
strong in the deep stroma, however only traces were
observed in the subepithelial stroma, as previously observed
in diestrus [20]. In the myometrium, the reaction was pre-
sent in the ECM and inside muscle cells of both layers, and
in the connective tissue between layers (Figure 1C).
In the E2+MPA-treated group, the immunoreaction
was present in the whole stroma, as a network of thin
filaments, except in the subepithelial stroma at the cleft
regions of the luminal epithelium branches. In the myo-
metrium, the immunostaining was moderate in the
ECM of the IML and strong in the EML and connective
tissue between layers (Figure 1D).
Relative expression of decorin mRNA
During the estrous cycle, there were no significant differ-
ences between groups. Ovariectomy significantly increased
decorin mRNA expression (≈4 fold) (p < 0.001) when
compared to estrus. Hormone replacement promoted
a significant reduction in d e c o r i ne x p r e s s i o ni nt h e
E2-treated group (≈4 fold) (p < 0.001) and MPA and E2
+MPA-treated groups (≈2 fold) (p < 0.01), when compared
to the non-treated ovariectomized group. Moreover, dec-
orin expression in the MPA and E2+MPA-treated groups
Table 2 Mouse oligonucleotide primers (5’®3’)
Gene Forward (F) and Reverse (R) primers Amplicon size Genbank #
Decorin F: TGCGATCCCTCAAGGTCTGCCT
R: TTGGCCAGACTGCCATTCTCCA
162 bp NM_007833.4
Biglycan F: AGGAGGCTTCAGGTTCAG
R: TAGCAGTGTGGTGTCAGG
171 bp NM_007542
Lumican F: CATTAGTCGGTAGTGTCAGTG
R: TGCCAGGAGGAACCATTG
171 bp NM_008524
Fibromodulin F: TGCCACATTCTCCAACCCAAGG
R: GAGCAGAGCCCAGCCAGCAG
116 bp NM_021355.3
Ywhaz F: GAAGCCACAATGTTCTTGGCCCAT
R: AAACCAACAGAGACTTGGAAGCAC
84 bp NM_011740.2
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Page 4 of 13was significantly higher than in diestrus and estrus, respec-
tively (≈2 fold) (p < 0.01) (Figure 2).
Biglycan immunolocalization
In the ovx and oil groups, the deposition of biglycan was
not observed in the endometrium and myometrium.
However, the immunoreaction was detected in the cyto-
plasm of mononucleated leukocytes (Figure 3A).
In the E2-treated group, the immunoreaction was pre-
sent in the endometrial stroma mainly around the luminal
and glandular epithelia. In the myometrium, the staining
was observed in the ECM of both smooth muscle layers,
especially the IML, and in the connective tissue between
them, particularly around blood vessels (Figure 3B).
I nt h eM P A - t r e a t e dg r o u p ,ad i ffuse brownish staining was
observed in the endometrial stroma. In the myometrium,
Figure 1 Immunoperoxidase for decorin. (A) Ovx group: decorin is present in the deep stroma, the external muscle layer and the connective
tissue between layers; (B) E2-group: the immunoreaction is seen in the whole endometrial stroma, especially around glands and under the
luminal epithelium (arrows), as well as in both layers of the myometrium; (C) MPA-group: the reaction is observed in the deep stroma and only
traces are seen in the superficial stroma (asterisk). In the myometrium, the reaction is present in both layers and the connective tissue; (D) E2
+MPA-group: the deposition of decorin is observed in the whole endometrial stroma and in both layers of the myometrium, as well ass in the
connective tissue between them. L = uterine lumen; G = endometrial gland; SS = superficial stroma; DS = deep stroma; V = blood vessel; IML =
internal muscle layer; EML = external muscle layer. Scale bar: 50 μm.
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Page 5 of 13the immunoreaction was moderate in both layers. It was
also present in the connective tissue between layers, espe-
cially around blood vessels (Figure 3C).
In the E2+MPA-treated group, biglycan was distribu-
ted as a network of thin brownish filaments, especially
in the subepithelial stroma, where leukocytic infiltration
was observed. In the myometrium, the immunoreaction
was more conspicuous in the IML and connective tissue
between layers, whereas a weak staining was observed in
the EML (Figure 3D).
Relative expression of biglycan mRNA
As observed for decorin, there was no significant differ-
ence in biglycan mRNA levels between estrus and dies-
trus. However, after ovariectomy there was a drastic
reduction in biglycan expression (≈3 fold) (p < 0.001),
when compared to estrus. A significant increase was
observed after hormone treatment with MPA (≈3f o l d )
(p < 0.05) and E2+MPA (≈5 fold) (p < 0.001), when
compared to the non-treated ovariectomized group.
Treatment with E2 alone did not promote significant
differences in biglycan mRNA levels in relation to the
ovariectomized group. However, it was significantly
lower than in estrus (≈2 fold) (p < 0.05) (Figure 4).
Lumican immunolocalization
In the ovx and oil groups, a faint immunoreaction was
observed in the scarce extracellular spaces of the endo-
metrial stroma, especially in the region of basement
membrane of the luminal epithelium, as well as in the
deep stroma. In the myometrium, the deposition of
lumican was weak in the connective tissue between
layers, in the EML and in the outer lining of the uterus,
the mesothelium (Figure 5A).
In the E2-treated group, lumican was widely distributed
in the whole endometrial stroma, in both layers of the
myometrium, around bundles of smooth muscle cells,
and in the connective tissue between layers (Figure 5B).
In the MPA-treated group, the immunoreaction was
present in the whole endometrial stroma as a diffuse
brownish staining, particularly in the deep stroma.
Under the luminal epithelium, only traces of immunor-
eaction were observed. In the myometrium, the immu-
nostaining was present only in the EML and connective
tissue between layers (Figure 5C).
In the E2+MPA-treated group, strong immunoreaction
was present in the whole endometrial stroma. In the
myometrium, the immunodeposition of lumican was
observed in the connective tissue between layers and a
weak staining was present in both myometrial layers,
especially in the EML (Figure 5D).
Relative expression of lumican mRNA
There were no significant differences in lumican expres-
sion between estrus and diestrus. After ovariectomy
there was a ≈2 fold increase in lumican mRNA levels
when compared to estrus. Hormone treatments did not
significantly alter lumican expression in the uterus,
when compared to the non-treated ovariectomized
group, maintaining a ≈2 fold increase in relation to
estrus (p < 0.05) (Figure 6).
Fibromodulin immunolocalization
In the ovx and oil groups, fibromodulin immunostaining
was not observed in the ECM of the endometrium and
myometrium. However, some mononucleated leukocytes
were immunoreactive in the endometrial stroma, as pre-
viously observed during the estrous cycle (Figure 7A).
In the E2-treated group, the immunoreaction was pre-
sent in the apical region of the luminal epithelium and in
the cytoplasm of mononucleated leukocytes observed in
the endometrial stroma. Strong immunostaining was pre-
sent in both myometrial layers, and around blood vessels
of the connective tissue between layers (Figure 7B).
In the MPA-treated group, the immunoreaction was
present in the luminal epithelium. The glandular secre-
tion was also immunoreactive to fibromodulin. In the
myometrium, the immunoreaction was strong in both
muscle layers, particularly the EML (Figure 7C).
In the E2+MPA-treated group, the staining pattern was
similar to that observed in the MPA group (Figure 7D).
Relative expression of fibromodulin mRNA
Fibromodulin mRNA expression was significantly higher in
diestrus than in estrus (≈2 fold) (p < 0.05). Ovariectomy
promoted a conspicuous increase in fibromodulin mRNA
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Figure 2 Decorin mRNA expression. Ovariectomy (ovx)
significantly increases decorin mRNA expression (~4 fold) when
compared with estrus. Hormone replacement promotes a significant
reduction in decorin expression in the E2-treated group (~4 fold)
and MPA and E2+MPA-treated groups (~2 fold). Values represent
the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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Page 6 of 13levels, when compared to estrus (≈7 fold) (p < 0.001). In
addition, fibromodulin expression was significantly reduced
after E2 treatment (≈7.5 fold) (p < 0.001), when compared
to the non-treated ovariectomized group. Moreover, MPA
and E2+MPA groups showed significantly augmented
expression when compared to diestrus (≈2 fold) (p < 0.01)
and estrus (≈2.5 fold) (p < 0.05), respectively (Figure 8).
Discussion
It is well established that in rodents the endometrium pro-
vides a unique environment, which allows or prevents
embryo implantation. It is also known that the endome-
trium undergoes dynamic reorganization during the
estrous cycle in preparation for these important events
[27]. Concerning the extracellular matrix, previous studies
Figure 3 Immunoperoxidase for biglycan. (A) Ovx group: the immunoreaction is absent in all uterine tissues, being detected only in the
cytoplasm of some leukocytes (arrowhead); (B) E2-group: the reaction is observed in the region of basement membrane of the luminal and
glandular epithelia (arrows) and in the myometrium; (C) MPA-group: strong diffuse reaction in the whole endometrial stroma. Moderate
immunoreaction is present in both layers of the myometrium and the connective tissue between them; (D) E2+MPA-group: the immunoreaction
is distributed as a network of thin filaments in the whole stroma. In the myometrium, the deposition of biglycan is observed in both layers and
connective tissue, being weak in the EML. L = uterine lumen; G = endometrial gland; SS = superficial stroma; DS = deep stroma; V = blood
vessel; IML = internal muscle layer; EML = external muscle layer. Scale bar: 50 μm.
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tion of ECM molecules in the distinct uterine tissues is
affected throughout the phases of the estrous cycle
[21,20,28].
In this study, the expression and distribution of dec-
orin, biglycan, lumican and fibromodulin in the endo-
metrium and myometrium were found to be ovarian
hormone-dependent and dose-related, evidencing that
those molecules play important roles in the preparation
for embryo implantation and successful gestation. Pre-
viously, San Martin et al [22] showed that decorin and
lumican are present in the superficial stroma on day
four of pregnancy, before decidualization. However, dec-
orin disappears from the endometrial stroma, following
a progesterone peak and the establishment of the
decidua. Interestingly, decorin is absent and lumican
deposition is reduced in the superficial stroma in the
diestrus phase [21], characterized by high levels of pro-
gesterone [29]. Coherently, the present results showed a
similar distribution pattern after MPA treatment.
The loss of decorin and reduction of lumican in this
context is functionally relevant, as both have anti-prolif-
erative activity [30,31], and in the beginning of decidua-
lization there is considerable DNA synthesis and cell
proliferation under strict hormonal control [32,33].
Moreover, decorin is known for its tumor-suppressive
role. Hu et al [34] demonstrated that decorin is able to
suppress prostate tumor growth through inhibition of
the EGFR signaling pathway. Additionally, Gu et al [35]
showed that decorin gene expression is down-regulated
in mammary tumor tissue when compared to normal
mammary gland tissue. Thus, our data suggest that P4
is capable of inhibiting or reducing, directly or through
other regulatory molecules, the expression and deposi-
tion of decorin in the superficial stroma, while stimulat-
ing the opposite effect in the deep stroma, which
corroborate high cell proliferation rate in the superficial
stroma (unpublished data) and the existence of two
genetically distinct subpopulations of endometrial
fibroblasts.
This proliferative phenomenon modulated by ECM
molecules is important for the preparation of the super-
ficial stroma to decidualize, while maintaining an undif-
ferentiated layer of endometrial fibroblasts in the deep
stroma, which is associated with reconstruction of the
endometrium in the post-partum period [36]. In addi-
tion, these results reinforce the existence of distinct
functional compartments of the mouse endometrium,
similar to the organization into basal and functional
layers of the human endometrium.
Moreover, the SLRPs studied herein are known to reg-
ulate collagen fibrillogenesis. Decorin is considered a
regulatory molecule, delaying the thickening of collagen
fibrils [17,37]. This study from Vogel and Trotter [37]
demonstrated that decorin, as well as lumican, link to
fibrillar collagens in vitro, stabilizing thin fibrils. Ameye
et al [38] showed that fibromodulin-deficient mice
synthesize abnormal and less numerous fibril bundles,
and these fibrils are often irregular and their diameter is
decreased. Decorin knock-out mice present irregular
fibrils with increased diameter in the endometrial
stroma of the pregnant mouse uterus. In addition, there
is an augment in lumican deposition in the endometrial
ECM of decorin-deficient mice, when compared to wild-
type littermate, demonstrating that both SLRPs compen-
sate each other’s expression in abnormal situations [39].
During early pregnancy in wild-type mice, the loss of
decorin, reduction of lumican and the deposition of
biglycan in the decidual ECM are related to the appear-
ance of thick collagen fibrils in the mature and
pre-decidua [21]. The only reports on the presence of
lumican in the uterus are part of previous studies from
our group [21,22,39] and the influence of ovarian hor-
mones on its expression in the uterus was uncertain
until now. It is known that lumican knock-out mice are
viable, but present reduced body weight and their litter
are considerably smaller, suggesting the relevance of this
proteoglycan for proper fetal growth [40].
A recent report by Markiewicz et al. [41] describes a
significant decrease in lumican, decorin and fibromodu-
lin mRNA levels in the skin of ovariectomized mice,
when compared to wild-type littermate. Contrarily, our
results showed that withdrawal of ovarian hormones
through ovariectomy promotes an augment in decorin,
lumican and fibromodulin mRNA expression in the
mouse uterus, and that E2 replacement induces a signif-
icant decrease in their mRNA levels. Indeed, microarray
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Figure 4 Biglycan mRNA expression. After ovariectomy there is a
drastic reduction in biglycan expression (~3 fold), when compared
with estrus. A significant increase is observed after hormone
treatment with MPA (~3 fold) and E2+MPA (~5 fold). Values
represent the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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Page 8 of 13data has previously demonstrated that decorin and
fibromodulin expression is down-regulated by E2 treat-
ment in the uterus of ovariectomized mice, corroborat-
ing our findings [42].
Despite the lack of deposition of both biglycan and
fibromodulin in the ECM of the endometrium and myo-
metrium in the ovx group, it is clear that withdrawal of
ovarian hormones promotes opposite effects on their
mRNA expression. Biglycan mRNA levels decreased,
whereas fibromodulin mRNA levels conspicuously
increased, suggesting that distinct post-transcriptional
modifications may occur among closely related mole-
cules. In fact, mature mRNA transcripts may be modified
by different reactions, such as alternative transcription
start sites, alternative splicing and alternative polyadeny-
lation site selection [43].
In the human myometrium, fibromodulin expression is
significantly higher in the secretory phase (progesterone
dominance) than in the proliferative phase (estrogenic
dominance) of the menstrual cycle [44]. We demonstrated
Figure 5 Immunoperoxidase for lumican. (A) Ovx group: A weak immunoreaction is observed in the endometrial stroma, especially under the
luminal epithelium (arrow) and in the deep stroma, as well as in the EML and connective tissue between muscle layers of the myometrium; (B)
E2-group: the reaction is present in the whole endometrial stroma and in both layers of the myometrium; (C) MPA-group: the reaction is present
in the whole stroma, however it is weak in the subepithelial stroma (asterisk). In the myometrium, deposition of lumican is observed in the EML
and connective tissue between layers; (D) E2+MPA-group: the immunoreaction is strong in the whole endometrial stroma. In the myometrium, a
weak staining is observed in both IML and EML, being strong in the connective tissue between them. L = uterine lumen; G = endometrial
gland; SS = superficial stroma; DS = deep stroma; V = blood vessel; IML = internal muscle layer; EML = external muscle layer. Scale bar: 50 μm.
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Page 9 of 13that, after hormone treatments, fibromodulin deposition
was strong in the myometrial ECM, as observed during
the estrous cycle and the early stages of pregnancy, which
suggests that fibromodulin acts in a hormone-dependent
manner in the remodeling of the myometrium. The pre-
sent findings also showed that deposition of all four SLRPs
was abolished from the internal and external layers of the
myometrium after ovariectomy, evidencing that this uter-
ine compartment is highly sensitive to fluctuations in ovar-
ian hormone levels.
Curiously, only biglycan and fibromodulin were
detected in the cytoplasm of uterine epithelial cells dur-
ing the estrous cycle and after hormone replacement.
Schaefer et al [45] showed the deposition of biglycan in
glomerular endothelial cells of renal tubules, whereas
Qian et al [46] demonstrated that fibromodulin is
expressed in gingival epithelium, indicating that epithe-
lial cells synthesize and secrete those proteoglycans in
the ECM and/or act in tissue remodeling through inter-
nalization of secreted molecules. Biglycan is a well-
known proteoglycan of pericellular matrices [12] and
modulates cell signaling events. Only in the E2-treated
group, biglycan was deposited preferentially in the
region of epithelial basement membrane and around
blood vessels, suggesting that its deposition is regulated
by E2 in a dose-dependent manner.
Hormone actions on target cells involve complex
molecular mechanisms. In our model, this complexity
may be exacerbated through the activity of metallopro-
teinases and growth factors, such as TGF-b. The glyco-
saminoglycan side chains attached to the proteoglycan
molecule possibly create a permissive environment for
the accumulation of growth factors in the ECM, thus
modulating cell metabolism.
Studies by Kim at al [47] showed that, in women, after
hormonal stimulus by E2 and P4, TGFb expression is up-
regulated in the endometrium, being down-regulated after
P4 withdrawal. Unpublished data from our group showed
that TGFb is widely distributed in the mouse endometrial
stroma in the phases of estrus and diestrus. A previous
report showed that TGFb 1 ,2a n d3a r ee x p r e s s e di n
mouse uterine tissues during early pregnancy [48]. Addi-
tionally, P4 is capable of inducing the expression of
TGFb1 by uterine epithelial cells and stromal fibroblasts
[47]. It is known that SLRPs modulate TGFb activity in
the uterine stroma and other tissues, controlling important
biological processes, such as cell proliferation and apopto-
sis [12,49]. It should be considered, however, that the reg-
ulation of cellular responses to growth factors depends not
only on the presence, but also on the concentration of
these molecules in the tissues.
Additionally, it is important to acknowledge the role
of specific proteases in this modulation process. For
instance, a previous report by Monfort et al [50]
described that decorin, lumican, biglycan and fibromo-
dulin are cleaved by metalloproteinase 13 (MMP-13) in
cartilage, at specific aminoacid sequences and at distinct
rates. Imai et al [51] showed that decorin is cleaved, at
different sites, by MMPs 2, 7 and especially MMP 3, a
well known proteoglycanase of many tissues. The con-
trolled cleavage of decorin is related to TGF-b release in
the ECM. Thus, MMPs may exert distinct actions under
specific hormonal influence. These molecules may also
generate bioactive peptides that play key roles in tissue
remodeling. Indeed, versican, an aggregating proteogly-
can widely distributed in the mouse endometrium, is
cleaved by ADAMTS, generating specific peptides that
most likely participate in biological processes, such as
cell migration, proliferation, and differentiation [52].
Another important variable in the context of steroid
hormone action is the regulation of mRNA stability of
several molecules, as well as the activity of RNases
[53-55]. Small RNA species, such as microRNAs and
small interference RNAs, are known to regulate gene
expression in a posttranscriptional way through cleavage
of the target mRNA or translational repression [56].
Steroid hormones, such as testosterone, have been iden-
tified as potential modulators of small RNA activity [57].
Moreover, the half-life of different RNA species is
important to determine the length of time in which
these mRNA molecules will act as template for protein
translation. For instance, Saceda et al [58] showed that
P4 promotes the increase in the half-life of its own
receptor’s mRNA from six to twelve hours, in primary
cell culture of endometrial fibroblasts. Presently, studies
are being developed in our laboratory to determine
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Figure 6 Lumican mRNA expression. After ovariectomy there is a
~2 fold increase in lumican mRNA levels, when compared with
estrus. Hormone treatments do not significantly alter lumican
expression in the uterus. Values represent the mean ± SEM. *p <
0.05; **p < 0.01; ***p < 0.001.
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Page 10 of 13whether E2 and P4 alter the mRNA stability of secreted
proteoglycans of the mouse uterus.
Conclusions
This and a previous study from our group suggest that
hormonal regulation of mRNA splicing, transcription
and post-transcriptional modifications, protein deposi-
tion in the ECM, and regulation of metalloproteinases
are important events to be considered when studying
the differential expression of ECM components, as well
as tissue remodeling, in the reproductive organs during
the sexual cycle and pregnancy.
Figure 7 Immunoperoxidase for fibromodulin. (A) Ovx group: the immunodeposition is absent from all uterine tissues, but may be observed
in the cytoplasm of some leukocytes (arrowhead); (B) E2-group: the immunoreaction is present in the apical cytoplasm of epithelial cells and in
leukocytes observed in the stroma (arrowheads). A strong immunoreaction is seen in both layers of the myometrium and in the connective
tissue between them; (C) MPA-group: the reaction is present in the luminal epithelium and in the secretion of endometrial glands. The
immunoreaction is seen in both layers of the myometrium, especially the EML; (D) E2+MPA-group: the staining pattern is similar to that
observed in the MPA group. L = uterine lumen; G = endometrial gland; SS = superficial stroma; DS = deep stroma; V = blood vessel; IML =
internal muscle layer; EML = external muscle layer. Scale bar: 50 μm.
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